LEGION 100 Trademark

Trademark Overview

On Friday, June 26, 2026, a trademark application was filed for LEGION 100 with the United States Patent and Trademark Office. The USPTO has given the LEGION 100 trademark a serial number of 99908104. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, June 26, 2026. This trademark is owned by Syncromune, Inc.. The LEGION 100 trademark is filed in the Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Medical devices for the treatment of solid tumor cancers which cause partial intratumoral cell lysis and which deliver direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis; Medical apparatus, namely, devices which cause partial intratumoral cell lysis and which permit infusion and injection for locally targeted administration at the site of partial intratumoral lysis of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof

Providing a website featuring information in the field of health and medicine; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis

Providing a website featuring information in the field of clinical trials; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis
legion 100

General Information

Serial Number99908104
Word MarkLEGION 100
Filing DateFriday, June 26, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, June 26, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesMedical devices for the treatment of solid tumor cancers which cause partial intratumoral cell lysis and which deliver direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis; Medical apparatus, namely, devices which cause partial intratumoral cell lysis and which permit infusion and injection for locally targeted administration at the site of partial intratumoral lysis of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof
Goods and ServicesProviding a website featuring information in the field of health and medicine; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis
Pseudo MarkLEGION HUNDRED
Pseudo MarkLEGION ONE HUNDRED
Goods and ServicesProviding a website featuring information in the field of clinical trials; conducting clinical trials of a system for the treatment of solid tumor cancers which causes partial intratumoral cell lysis and which delivers direct infusion of one or more Active Pharmaceutical Ingredients (APIs), whether biological or chemical agents or mixtures and formulations thereof into the tumor or to a localized region of the body at the site of partial intratumoral cell lysis

Classification Information

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateFriday, June 26, 2026
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 26, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 26, 2026
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSyncromune, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33308
US

Trademark Events

Event DateEvent Description
Friday, June 26, 2026NEW APPLICATION ENTERED
Friday, June 26, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

legion lysis which partial intratumoral cell tumor ingredients apis whether biological